Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Relationship between serum RANKL and RANKL in bone|
|Citation:||Osteoporosis International, 2011; 22(10):2597-2602|
|Publisher:||Springer London Ltd|
|D. M. Findlay, G. J. Atkins|
|Abstract:||It is now well accepted that the molecule receptor activator of NFκB ligand (RANKL) and osteoprotegerin play key roles in regulating physiological and pathological bone turnover. There are a large number of published reports of circulating RANKL levels in both health and pathology. However, interpretation of these data has been elusive, and the relationship between circulating RANKL and RANKL levels in bone is still not clear. This review explores this subject, documenting the possible origins of circulating RANKL and suggesting additional information that is required before serum RANKL levels can provide useful diagnostic or research information.|
|Keywords:||Bone; mRNA; RANK ligand; Serum|
|Rights:||© International Osteoporosis Foundation and National Osteoporosis Foundation 2011|
|Appears in Collections:||Orthopaedics and Trauma publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.